Patents Examined by My-Chau T Tran
  • Cycloalkyl-substituted imidazole derivative
    Patent number: 9340531
    Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R1, R2, and R3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; R4 represents a hydrogen atom or a prodrug group; and Y represents —CH2—CHR5—CH2—NHR6 (wherein R5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: May 17, 2016
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Tsutomu Nagata, Masahiro Inoue, Yuka Ashida, Kengo Noguchi, Makoto Ono
  • Anti-obesity potential of Calebin A
    Patent number: 9328330
    Abstract: The present invention discloses the potential of Calebin A in inhibiting adipogenesis and applications thereof in obesity management. The present invention elucidates the potential of Calebin A to favorably modulate biochemical markers associated with obesity. Notable biomodulatory properties of Calebin A include inhibiting leptin production, increasing adiponectin expression and inhibiting local (adipocyte) and systemic inflammation caused by pro-inflammatory cytokines Tumor Necrosis Factor (TNF-?), Interleukin-6 (IL-6) and Interleukin-1 (IL-1?).
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: May 3, 2016
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Anju Majeed, Bani Sarang, Anjali Pandey
  • Methods for improving brain development and cognitive function using beta-hydroxy-beta methylbutyrate
    Patent number: 9326956
    Abstract: Disclosed are methods for enhancing neural function in an individual, such as an older adult. The methods include administering nutritional compositions comprising HMB to the individual. The nutritional compositions provide benefits for individuals that have or may be at risk of having cognitive decline, cognitive impairment, and neural dysfunction, typically resulting from cognitive diseases associated with neurodegenerative diseases.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: May 3, 2016
    Assignee: Abbott Laboratories
    Inventors: Jose Maria Lopez Pedrosa, Manuel Manzano Martin, Alejandro Barranco Perez, Maria Ramirez Gonzalez, Ricardo Rueda Cabrera
  • Oleyl phosphocholine
    Patent number: 9326989
    Abstract: The invention relates to the use of oleyl phosphocholine and oleyl-phospho-(N.N.-dimethyl-N-ethyl)-ethyl-ammonium for the long-term and continuous treatment of serious illnesses, such as cancer, leishmaniasis, ehrlichiosis, multiple sclerosis and psoriasis, in addition to other indications mentioned in the application.
    Type: Grant
    Filed: March 26, 2008
    Date of Patent: May 3, 2016
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventor: Hansjörg Eibl
  • Ceftolozane-tazobactam pharmaceutical compositions
    Patent number: 9320740
    Abstract: Pharmaceutical compositions are provided in unit dosage forms comprising ceftolozane and tazobactam in separate unit dosage form containers, ceftolozane prepared in the absence of tazobactam, tazobactam prepared in the absence of ceftolozane, and/or compositions where ceftolozane and tazobactam are first combined within a unit dosage form container.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 26, 2016
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Joseph Terracciano, Nicole Miller Damour, Chun Jiang, Giovanni Fogliato, Giuseppe Alessandro Donadelli, Dario Resemini
  • Enhancer of survival of transplanted organ
    Patent number: 9314443
    Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: April 19, 2016
    Assignees: National Center for Child Health and Development, SBI Pharmaceuticals Co., Ltd.
    Inventors: Ko Rii, Kiwamu Takahashi, Naomi Haga, Fuminori Abe, Tohru Tanaka, Motowo Nakajima, Hidenori Ito
  • Methods of treating and preventing vascular instability diseases
    Patent number: 9314457
    Abstract: Methods are provided of treating and preventing stroke diseases, such as cerebral cavernous malformation, by the administration of tempol and/or cholecalciferol.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: April 19, 2016
    Assignee: THE UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Christopher C. Gibson, Dean Y. Li
  • Enhanced stability of novel liquid compositions
    Patent number: 9308166
    Abstract: The present invention relates to compositions of pharmaceutical agents in combination with additional pharmaceutical agents in a mixture of polyethylene glycol, polyvinylpyrrolidone, and propylene glycol and a process of making the compositions.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: April 12, 2016
    Assignee: Pfizer Inc.
    Inventors: Gary Robert Agisim, Robert Alan Friedline, Shivangi Akash Patel, César Iván Sertzen, Vanessa Rose Shepperson
  • Application of cinchona alkaloid derivatives as cytotoxic compounds
    Patent number: 9301956
    Abstract: 9-O-propargyl ethers of cinchona alkaloids of general formula represented by formula 1 wherein respective ethers have the following absolute configuration at C-8 and C-9 atoms: (8R,9S)-cinchonine configuration or (8R,9R)-9-epicinchonine configuration are useful in treatments of at least one of breast cancer, cervical cancer, lung cancer and nasopharynx cancer.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: April 5, 2016
    Assignee: ADAM MICKIEWICZ UNIVERSITY
    Inventors: Lech Celewicz, Karol Kacprzak, Piotr Ruszkowski
  • Omega-3 phospholipid supplements for improved brain maturity
    Patent number: 9295683
    Abstract: The invention relates to omega-3 phospholipid supplements for use in adolescents, and in particular to use omega-3 phospholipid supplements to improve or support brain maturity age. In preferred embodiments, the omega-3 phospholipid is krill oil.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: March 29, 2016
    Assignee: AKER BIOMARINE ANTARCTIC AS
    Inventors: Kjetil Berge, Lena Burri
  • Pharmaceutical composition for preventing or treating diabetes or fatty liver containing a CYP4A inhibitor as an active ingredient
    Patent number: 9295667
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating diabetes or fatty liver, and more specifically relates to a pharmaceutical composition for preventing or treating diabetes or fatty liver containing a CYP4A (cytochrome P450A) inhibitor as an active ingredient. According to the present invention, the CYP4A inhibitor suppresses endoplasmic reticulum stress, reduces the blood insulin concentration and suppresses apoptosis of liver cells, and hence exhibits effects in preventing or treating diabetes or fatty liver.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: March 29, 2016
    Assignee: Korea Basic Science Institute
    Inventors: Gun-Hwa Kim, Soohyun Kim, Jong-Soon Choi, Seung Il Kim, Edmond Changkyun Park
  • Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
    Patent number: 9289406
    Abstract: The present disclosure provides methods for treating hepatic encephalopathy (HE) and for optimizing and adjusting nitrogen scavenging drug dosage for subjects with HE.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: March 22, 2016
    Assignee: Horizon Therapeutics, Inc.
    Inventors: Bruce Scharschmidt, Masoud Mokhtarani
  • CDDO-Me amino acid conjugates and methods of use
    Patent number: 9290455
    Abstract: 2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid amino acid derivatives having antiinflammatory properties are provided. Pharmaceutical compositions and methods for preventing or treating inflammation or a disease or condition mediated by inflammation are described.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: March 22, 2016
    Assignee: Trustees of Dartmouth College
    Inventors: Michael B. Sporn, Karen T. Liby, Martine Cao, Evans O. Onyango, Liangfeng Fu, Gordon W. Gribble
  • Compositions and methods for treating or preventing obesity in a subject in need thereof
    Patent number: 9283201
    Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent obesity.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 15, 2016
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventor: Joseph S. Zakrzewski
  • Methods and compositions for treatment of epithelial wounds
    Patent number: 9283175
    Abstract: This invention relates to treatment of epithelial wounds. In particular, the invention relates to methods and formulations for treating epithelial wounds based on application of an opioid antagonist such as naltrexone.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: March 15, 2016
    Inventors: Ian S. Zagon, Patricia J. McLaughlin, Joseph W. Sassani
  • Ascorbic acid salt of sunitinib
    Patent number: 9278955
    Abstract: The present invention relates to an ascorbic acid salt of sunitinib and a process for its preparation. The present invention further provides a crystalline Form I of an L-ascorbic acid salt of sunitinib.
    Type: Grant
    Filed: January 6, 2014
    Date of Patent: March 8, 2016
    Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Hari Babu Matta, Mahavir Singh Khanna, Mohan Prasad
  • Use of TRPA1 antagonists to prevent or treat infections caused by biological-warfare agents
    Patent number: 9260430
    Abstract: Provided are methods for preventing and treating injuries caused by exposure to biological warfare agents. The methods include administering to a subject in need thereof an effective amount of a TRPA1 antagonist or a pharmaceutically acceptable salt thereof. In an embodiment the TRPA1 antagonist is selected from the group consisting of compounds of formula I and compounds of formula II as described herein.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: February 16, 2016
    Assignee: HYDRA BIOSCIENCES, INC.
    Inventor: Magdalene M. Moran
  • Water-soluble derivatives and prodrugs of acacetin and methods of making and using thereof
    Patent number: 9260461
    Abstract: Water-soluble derivatives and/or prodrugs of acacetin are described herein. The compounds can be used as cardioprotection agents against myocardial infarction induced by ischemia-reperfusion. In one embodiment the compounds are used to treat ischemic cardiac diseases. In the preferred embodiment, the compounds are used to treat and/or prevent myocardial infarction in humans.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: February 16, 2016
    Assignee: Versitech Limited
    Inventors: Gui-Rong Li, Feng Lin
  • Stable quick dissolving dosage form comprising amoxicillin and clavulanic acid
    Patent number: 9254261
    Abstract: A quick dissolving pharmaceutical formulation is disclosed. In one embodiment, the formulation includes at least the following components: (1) from about 35 to about 50 weight percent amoxicillin or a pharmaceutically acceptable salt thereof; (2) from about 2.0 to about 12 weight percent clavulanic acid or a pharmaceutically acceptable salt thereof; (3) from about 30 to about 40 weight percent mannitol; (4) from about 2 to about 7 weight percent crospovidone; (5) from about 0.5 to about 2.0 weight percent colloidal silicon dioxide; and (6) from about 2.0 to about 5.0 weight percent sodium stearyl fumarate. A method for making a quick dissolving pharmaceutical tablet is also disclosed.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: February 9, 2016
    Assignee: Sandoz AG
    Inventors: Rok Staric, Marko Oblak, Tanja Rozman Peterka, Veronika Debevec
  • Transdermal hormone replacement therapies
    Patent number: 9248136
    Abstract: Hormone replacement therapies are provided comprising solubilized progesterone alone and optionally with an estrogen, cyclic/sequential and continuous-combined dosing, and administered via transdermal HRT delivery systems.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: February 2, 2016
    Assignee: TherapeuticsMD, Inc.
    Inventors: Brian A. Bernick, Julia M. Amadio, Peter H. R. Persicaner, Janice Louise Cacace, Neda Irani, Frederick D. Sancilio